Journal article
Targeting Phenotypic Plasticity in Prostate Cancer
Current molecular biology reports, Vol.3(3), pp.183-196
07/18/2017
DOI: 10.1007/s40610-017-0070-x
Abstract
Purpose of Review
Despite advances in the development of new cancer therapies, cancer metastasis, along with drug resistance, remains the major driver of mortality in patients with advanced cancer. Therefore, there is an urgent need to develop new cancer therapeutics able to target metastasis.
Recent Findings
Phenotypic plasticity has gained an increasing interest in cancer research as it may facilitate metastatic outgrowth and therapeutic resistance by enabling cancer cells to adapt to new or stressful conditions. For this reason, phenotypic plasticity has become a promising target for the development of new therapeutics. For the last decade, numerous screening efforts have been developed in order to identify compounds targeting epithelial-to-mesenchymal transition (EMT)-like or cancer stem cells, both populations being associated with phenotypic plasticity in cancer.
Summary
In this review, we described the different screening approaches that led to the identification of potential anti-EMT and anti-cancer stem cell compounds in cancer, with an emphasis on prostate cancer.
Details
- Title: Subtitle
- Targeting Phenotypic Plasticity in Prostate Cancer
- Creators
- Marion Vanneste - University of IowaMichael D. Henry - Roy J. and Lucille A. Carver College of Medicine
- Resource Type
- Journal article
- Publication Details
- Current molecular biology reports, Vol.3(3), pp.183-196
- Publisher
- Springer International Publishing
- DOI
- 10.1007/s40610-017-0070-x
- ISSN
- 2198-6428
- eISSN
- 2198-6428
- Language
- English
- Date published
- 07/18/2017
- Academic Unit
- Molecular Physiology and Biophysics; Pathology; Radiation Oncology
- Record Identifier
- 9984302186202771
Metrics
1 Record Views